Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials
In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age. Solicited adverse events (AEs) were collected for 7 days post-each dose in a stud...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2020-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a426b076a4c9441b8ceb65db156795c0 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Romulo Colindres |e author |
| 700 | 1 | 0 | |a Valentine Wascotte |e author |
| 700 | 1 | 0 | |a Alain Brecx |e author |
| 700 | 1 | 0 | |a Christopher Clarke |e author |
| 700 | 1 | 0 | |a Caroline Hervé |e author |
| 700 | 1 | 0 | |a Joon Hyung Kim |e author |
| 700 | 1 | 0 | |a Myron J. Levin |e author |
| 700 | 1 | 0 | |a Lidia Oostvogels |e author |
| 700 | 1 | 0 | |a Toufik Zahaf |e author |
| 700 | 1 | 0 | |a Anne Schuind |e author |
| 700 | 1 | 0 | |a Anthony L. Cunningham |e author |
| 245 | 0 | 0 | |a Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials |
| 260 | |b Taylor & Francis Group, |c 2020-11-01T00:00:00Z. | ||
| 500 | |a 2164-5515 | ||
| 500 | |a 2164-554X | ||
| 500 | |a 10.1080/21645515.2020.1741312 | ||
| 520 | |a In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age. Solicited adverse events (AEs) were collected for 7 days post-each dose in a study sub-cohort. The incidence of reported solicited AEs was higher for RZV compared to placebo recipients. Since reactogenicity may contribute to a person's willingness to be vaccinated, knowing about expected reactogenicity might help keep high compliance with the second dose. This post hoc analysis assessed the intensity of solicited AEs post-dose 2 reported to the same event's intensity post-dose 1. Intensity was graded from 0 to 3, grade 3 indicating the highest severity. Of the vaccinees who did not experience a specific AE post-dose 1, 72.6-91.7% did not experience the same event after dose 2. Although the frequency of grade 3 AEs post-dose 2 was the highest in participants reporting the same AEs at grade 3 post-dose 1, 65.8-89.3% of vaccinees with grade 3 specific AEs post-dose 1 reported the same AEs at lower intensity post-dose 2. These data can help inform health-care professionals about the frequency and intensity of AEs post-dose 2 with respect to post-dose 1. | ||
| 546 | |a EN | ||
| 690 | |a recombinant herpes zoster vaccine | ||
| 690 | |a reactogenicity | ||
| 690 | |a doses | ||
| 690 | |a healthcare professionals | ||
| 690 | |a adverse events | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 16, Iss 11, Pp 2628-2633 (2020) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/21645515.2020.1741312 | |
| 787 | 0 | |n https://doaj.org/toc/2164-5515 | |
| 787 | 0 | |n https://doaj.org/toc/2164-554X | |
| 856 | 4 | 1 | |u https://doaj.org/article/a426b076a4c9441b8ceb65db156795c0 |z Connect to this object online. |